On October 9, 2024 Schrödinger (Nasdaq: SDGR) reported that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program, will be presented during poster sessions at the 36th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium (ENA 2024) taking place October 23-25, 2024 in Barcelona, Spain (Press release, Schrodinger, OCT 9, 2024, View Source [SID1234647124]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SGR-3515 presentation will include data further characterizing SGR-3515 in preclinical oncology models. Wee1 and Myt1 kinases regulate the cell cycle and DNA damage response, allowing time for DNA repair before cell division takes place. Concurrent loss of function or inhibition of Wee1 and Myt1 confers selective vulnerability in cancer cells, a mechanism referred to as synthetic lethality. The preclinical data indicate that SGR-3515 has a differentiated profile and support its continued development as a potential therapy for patients with advanced solid tumors. A Phase 1 clinical trial in this patient population is ongoing.

Additionally, preclinical data will be presented on the discovery of highly selective PRMT5-MTA inhibitors. Schrödinger has identified a novel series of selective, potent PRMT5-MTA inhibitors and is optimizing lead compounds for use in peripheral and brain tumors.

Details of the data presentations are as follows:

Title: Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models
Abstract Number: 147
Presentation Date and Time: Wednesday, October 23, 2024, 12PM-2PM CEST (6AM-8AM EDT)
Location: Exhibit Hall, Barcelona International Convention Centre

Title: Discovery of a highly MTA-synergistic series of PRMT5 inhibitors for the treatment of MTAP-deficient tumors by virtual screening technology
Abstract Number: 372
Presentation Date and Time: Friday, October 25, 2024, 9AM-3PM CEST (3AM-9AM EDT)
Location: Exhibit Hall, Barcelona International Convention Centre